Pembrolizumab for Mucosal melanoma|Melanoma

Inclusion criteria

• {"criterion_text":"- 1. Be willing and able to provide written informed consent/assent for the trial.\n- 2. Be >18 years of age on day of signing informed consent.\n- 3. Present with a resectable mucosal melanoma.\n- 4. Be eligible for surgical treatment (without any contraindications).\n- 5. Be eligible for adjuvant radiotherapy.\n- 6. Have measurable disease based on RECIST 1.1.\n- 7. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion. Newly-obtained is defined as a specimen obtained up to 6 weeks (42 days) prior to initiation of treatment on Day 1. Subjects for whom newly-obtained samples cannot be provided (e.g. inaccessible or subject safety concern) may submit an archived specimen only upon agreement from the Sponsor.\n- 8. Have a performance status of 0 or 1 on the ECOG Performance Scale.\n- 9. Demonstrate adequate organ function as defined in table 1, all screening labs should be performed within 10 days of treatment initiation.\n- 10. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n- 11. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.\n- 12. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n- 13. Patient affiliated to a social security system or beneficiary of the same\n- 14. Not having any contraindication for lenvatinib treatment"}

Exclusion criteria

• {"criterion_text":"- 1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n- 2. Has a metastatic disease.\n- 3. Has a non resectable melanoma.\n- 4. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (except topical or inhaled steroids) or any other form of immunosuppressive therapy within 2 weeks prior to the first dose of trial treatment.\n- 5. Has a known history of active TB (Bacillus Tuberculosis)\n- 6. Hypersensitivity to pembrolizumab or any of its excipients.\n- 7. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to D1 of study treatment or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n- 8. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks or 5 half-life times (whatever the shorter) prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.\n- 9. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n- 10. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.\n- 11. Has active autoimmune and/or immune mediated inflammatory disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n- 12. Has known history of, or any evidence of active, non-infectious pneumonitis.\n- 13. Has an active infection requiring systemic therapy.\n- 14. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n- 15. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n- 16. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n- 17. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n- 18. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\n- 19. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).\n- 20. Has received a live vaccine within 30 days of planned start of study therapy.\n- 21. Major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing\n- 22. Has a prior history of organ transplant including allogeneic stem cell transplant\n- 23. Has a LVEF below the institutional (or local laboratory) normal range, as determined by multigated acquisition (MUGA) or echocardiogram (ECHO)\n- 24. Has an uveal melanoma\n- For the cohort B, patients must be excluded if one of the following additional criteria is met : 25. Uncontrolled blood pressure (Systolic BP>140 mmHg or diastolic BP >90 mmHg) in spite of an optimized regimen of antihypertensive medication\n- 26. Electrolyte abnormalities that have not been corrected\n- 27. Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 12 months of the first dose of study drug, or cardiac arrhythmia requiring medical treatment at Screening\n- 28. Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage. The degree of tumor invasion/infiltration of major blood vessels (e.g. carotid artery) should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis following lenvatinib therapy\n- 29. Subjects having > 1+ proteinuria on urine dipstick testing unless a 24-hour urine collection for quantitative assessment indicates that the urine protein is <1 g/24 hours.\n- 30. Subjects who have not recovered adequately from any toxicity from other anti- cancer treatment regimens and/or complications from major surgery prior to starting therapy. Withhold lenvatinib for at least 1 week prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing.\n- 31. The participant has severe hypersensitivity (≥Grade 3) to lenvatinib and/or any of its excipients.\n- 32. Has presence of a gastrointestinal condition including malabsorption, gastrointestinal, anastomosis, or any other condition that might affect the absorption of lenvatinib.\n- 33. Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula.\n- 34. Has clinically significant hemoptysis or significant tumor bleeding within 3 weeks prior to the first dose of study drug.\n- 35. Prolongation of QTcF interval to >480 ms"}

Primary endpoints

• {"endpoint_text":"- Disease free survival, defined as the time between the inclusion in the trial and the date of the first event defined as local, regional, distant relapse or death whatever the cause.","definition_or_measurement_approach":"Defined as the time between inclusion in the trial and the date of the first event defined as local, regional, distant relapse or death (any cause); primary endpoint measured as disease-free survival at 2 years."}

Secondary endpoints

• {"endpoint_text":"- Overall survival (OS)","definition_or_measurement_approach":"Overall survival measured as time from inclusion to death from any cause."}
• {"endpoint_text":"- Locoregional control (Time to locoregional relapse, TTLRC)","definition_or_measurement_approach":"Time to locoregional relapse (time from inclusion to locoregional relapse)."}
• {"endpoint_text":"- Efficacy (Objective response, according to RECIST 1.1), after neoadjuvant therapy","definition_or_measurement_approach":"Objective response assessed by RECIST 1.1 criteria after neoadjuvant therapy."}
• {"endpoint_text":"- Pathological response after neoadjuvant therapy","definition_or_measurement_approach":"Pathological response assessed on surgical specimens following neoadjuvant therapy."}
• {"endpoint_text":"- Acute toxicity (CTC-NCI V4)","definition_or_measurement_approach":"Acute toxicity graded using CTCAE (NCI) version 4."}
• {"endpoint_text":"- Translational criteria o Ex vivo response to anti-PD1 o Prognostic value of biomarkers including PDL1 expression and mutational load o Variation of circulating lymphocytes (before–after treatment)","definition_or_measurement_approach":"Exploratory/translational endpoints including ex vivo response to anti-PD1; evaluation of tumor PDL1 expression, tumor mutational load and other immunologic biomarkers; and changes in circulating lymphocyte subpopulations and soluble immune factors before and during treatment."}

France

Earliest CTIS Part Ii Submission Date

14-06-2024

Latest Decision Or Authorization Date

18-08-2025

Processing Time Days

430

Number Of Sites

6

Number Of Participants

60

Primary sponsor

Full Name

Institut Gustave Roussy

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

France